We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
-8.24%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$482M
AUM Growth
-$151M
Cap. Flow
-$70.7M
Cap. Flow %
-14.68%
Top 10 Hldgs %
78.28%
Holding
34
New
5
Increased
8
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$15.5M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$11.7M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$11.3M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$9.29M
5
PRQR icon
ProQR Therapeutics
PRQR
+$8.8M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$49.4M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$41.7M
3
EXEL icon
Exelixis
EXEL
+$3.39M
4
ARRY
Array Biopharma Inc
ARRY
+$3.31M
5
QLTI
QLT Inc
QLTI
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 78.72%
2 Miscellaneous 21.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXRT
26
DELISTED
Vaxart
VXRT
$1.08M 0.22%
39,627
– –
ANTH
27
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.07M 0.22%
69,953
– –
QURE icon
28
uniQure
QURE
$2.98B
$981K 0.2%
106,500
-18,500
-15% -$203K
PTN
29
Palatin Technologies
PTN
$18.6M
$698K 0.14%
601
-688
-53% -$829K
PRTK
30
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$304K 0.06%
12,500
– –
EXEL icon
31
Exelixis
EXEL
$14.1B
– –
-1,000,000
Closed -$3.39M
BIND
32
DELISTED
BIND THERAPEUTICS INC
BIND
– –
-116,000
Closed -$1.53M
1
2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q3 2014 Portfolio in Review

As of Q3 2014, BVF Inc held 34 positions worth $482M, down 24% from $632M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

BVF Inc withdrew a net $70.7M in Q3 2014, closing 2 positions and reducing 7 holdings. Its most notable exit was Exelixis, an estimated $3.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

Against the trend, BVF Inc opened a new position in Loxo Oncology, Inc worth $15.7M.

  • BVF Inc's largest Q3 2014 buy was Loxo Oncology, Inc: 1,192,202 shares worth $15.7M.
  • BVF Inc added most to RECEPTOS INC COM STK (DE) in Q3 2014, an estimated $11.3M increase.
  • BVF Inc's biggest Q3 2014 reduction was Ironwood Pharmaceuticals, cutting an estimated $49.4M.
  • BVF Inc fully exited Exelixis in Q3 2014, selling an estimated $3.39M.
  • BVF Inc's ten largest holdings make up 78% of its $482M portfolio in Q3 2014.
  • BVF Inc opened 5 new positions and closed 2 in Q3 2014.
  • BVF Inc's portfolio value fell 24% quarter-over-quarter to $482M.

Based on BVF Inc's 13F filing for Q3 2014, filed 14 Nov 2014.